Luciano Nava
Papers
2
Total Citations
132
H-Index
2
About
Dr. Luciano Nava is a distinguished urologic surgeon and researcher whose work has significantly advanced the understanding and management of prostate cancer. His primary research focuses on improving the accuracy of prostate cancer diagnosis and prognostication through novel biomarkers. Dr. Nava’s most impactful contribution is his pioneering investigation into the Prostate Health Index (PHI) and its components, particularly the isoform p2PSA. His landmark 2011 study, cited over 120 times, demonstrated that preoperative %p2PSA and PHI scores can independently predict adverse pathologic outcomes, such as extracapsular extension and seminal vesicle invasion, in men undergoing radical prostatectomy. This work has helped clinicians better stratify patients for treatment planning, potentially reducing unnecessary interventions. Beyond biomarkers, Dr. Nava has also contributed to the refinement of surgical techniques, including nerve-sparing laparoscopic cystectomy, showcasing his commitment to improving oncologic outcomes while preserving quality of life. His research bridges the gap between molecular diagnostics and surgical practice, offering tangible tools for personalized prostate cancer care.
Research Focus
Key Achievements
Top Papers
- 1
- 2Nerve-sparing laparoscopic cystectomy8 citations · 2005